Coulter Partners places Neil Anderson as Chief Business Officer at MitoRx Therapeutics
Coulter Partners, the global expert building leadership teams for Health, Science, and Technology innovation businesses, successfully led a search assignment for MitoRx Therapeutics and is pleased to announce the placement of Neil Anderson, Ph.D., as Chief Business Officer.
MitoRx Therapeutics is a biotech company targeting the restoration of healthy mitochondrial metabolism in high-risk obesity. Its first-in-class small molecule asset, MTRX31, targets the elimination of ectopic fat from affected organs by resetting mitochondrial function rather than suppressing appetite.
Dr Anderson brings more than 20 years of industry experience, combining a scientific background with senior business development and investment roles. His career, including his most recent role at Novo Nordisk and an earlier position as Vice President and Global Head of Business Development at Evaxion Biotech, has given him deep insight into identifying and developing strategic opportunities in cardiometabolic disease, alongside an extensive network across the global biopharma sector.
Jon Rees, Ph.D., CEO of MitoRx Therapeutics said:
We are delighted to welcome Neil Anderson to MitoRx at an important stage in our growth and development. He has spent his career sourcing, evaluating, and executing transactions across both large pharma and biotech, and that experience, together with his deep industry contacts, will be valuable as we advance MTRX31 towards the clinic and look to maximize the potential of this attractive drug candidate. Having already worked with Coulter Partners on the appointment of our Chief Scientific Officer last year, we partnered with them once again which helped us secure an outstanding cardiometabolic specialist Chief Business Officer in Neil Anderson.
Commenting on his appointment, Neil Anderson said:
I was attracted to the role at MitoRx by the quality of the science and caliber of the team. Today’s obesity medicines have focused heavily on how much weight can be lost, but not the quality or durability of that loss in patients at highest risk of serious illness. MTRX31 has delivered fat-selective weight loss, preserved lean mass, and restored metabolic function without suppressing appetite in preclinical studies, which I believe makes it a very attractive proposition for the 30-40% of people living with metabolically unhealthy obesity.cCoulter Partners ran an excellent process. Their understanding of MitoRx, the opportunity, and the wider market made for a highly engaging dialogue from the outset and gave me a strong sense of the team and its ambitions.
Kay Wardle, Ph.D., Managing Partner at Coulter Partners, said:
Obesity and cardiometabolic disease are among the most dynamic areas in biopharma today, and competition for proven talent is exceptionally strong. For MitoRx, the brief called for someone who could combine deep sector knowledge with hands-on experience across investment, business development, and strategic transactions. Neil brings that rare breadth across both pharma and biotech, together with a highly relevant network and deep understanding of the cardiometabolic landscape. We are delighted to have partnered with MitoRx to secure him at such an important stage in the company’s development.
